After more than half a century of pharmacogenomic research, the clinical use of pharmacogenomic testing remains uncommon, despite many examples showing that inherited genomic variation causes substantial interindividual differences in drug effects. Since the sequences of pooled human genomes were made public,12 only a handful of pharmacogenetic tests have been translated into clinical laboratory tests. With the adoption of genetic non-discrimination laws,3 fewer legal arguments can be made for withholding genetic tests from medical records. We address some of the reasons underlying genetic exceptionalism, as it applies to the slow adoption of pharmacogenomics, and discuss the steps we are taking to combat this deficiency in clinical practice.
展开▼
